NEWS4 April 2014
US — IMS Health has priced its initial public offering at $20 a share, which stands to generate $1.3bn for the company and its private equity owners.
The healthcare data firm is putting 52m shares up for sale, with the resulting proceeds – around $1bn – earmarked for paying down existing long-term debt.
Meanwhile, the investment firms that took IMS private in a $5bn deal in 2010 will sell 13m shares – returning $260m to their coffers.
IMS filed for an IPO in January this year. The offering is expected to close on 9 April. Shares are expected to begin trading on the New York Stock Exchange (NYSE) today under the ticker symbol IMS.
Pictured is IMS CEO Ari Bousbib.
UPDATE: IMS shares opened at $22.18 on the NYSE this morning. As of 10.15am ET they were trading at $22.85.
The world's leading job site for research and insight
Hasson Associates
Senior Research Manager / Associate Director
£300–300 per day
Resources Group
Analytics Associate Director – Consumer CX – Key Tech client
£50,000–£60,000 + Bens
Hasson Associates
Associate Director, Technology
£40000–65000
Featured company
-
Town/Country: London
Tel: +44 (0)20 7490 7888
Kudos Research are leading providers of premium quality UK and International Telephone Data-Collection. Specialising in hard to reach B2B and Consumer audiences, we achieve excellent response rates and provide robust, actionable, verbatim-rich data. Methodologies include CATI, . . .
-
Town/Country: Aylesbury
Tel: +44 (0)1296 632578
2Europe is an award-winning (Quirk's, RAR Awards), full-service market research agency which specialises in international B2B market research. We are recognised as one of the top market research agencies in the UK . . .
Related Articles
© Copyright 2022 Research Live
0 Comments